Hypertrophic cardiomyopathy--sports-related aspects of diagnosis, therapy, and sports eligibility
- PMID: 14750008
- DOI: 10.1055/s-2003-45227
Hypertrophic cardiomyopathy--sports-related aspects of diagnosis, therapy, and sports eligibility
Abstract
Hypertrophic cardiomyopathy (HCM) is one of the primary causes of sudden cardiac death in athletes < 35 years of age. The highest risk of sudden cardiac death is associated with syncope, early age, extreme ventricular hypertrophy, ventricular tachycardia, and a family history of sudden death. The relative risk in competitive sports is unknown. Usually, sports eligibility is rejected. However, some athletes with HCM tolerate extreme athletic lifestyles without complications. Sports-related aspects of diagnosis, therapy, and sports eligibility are presented, and discussed. Two case reports are presented: a 20-year-old professional soccer player and a 66-year-old long-distance runner. Athletes with HCM should not participate in most competitive sports with the possible exception of those of low dynamic and low static intensity. Participation in low to moderate athletic activities may be allowed in selected patients without risk factors and > 35 years of age.
Comment in
-
A crucial point: the early diagnosis of increased risk subjects before sudden cardiac death.Int J Sports Med. 2004 Nov;25(8):641-2; author reply 643. doi: 10.1055/s-2004-821302. Int J Sports Med. 2004. PMID: 15532011 No abstract available.
Similar articles
-
Hypertrophic cardiomyopathy and other causes of sudden cardiac death in young competitive athletes, with considerations for preparticipation screening and criteria for disqualification.Cardiol Clin. 2007 Aug;25(3):399-414, vi. doi: 10.1016/j.ccl.2007.07.006. Cardiol Clin. 2007. PMID: 17961794 Review.
-
[Hypertrophic cardiomyopathy and sports activities].Rev Prat. 2001 Jun 30;51(12 Suppl):S51-3. Rev Prat. 2001. PMID: 11505870 French.
-
Prevalence of hypertrophic cardiomyopathy in highly trained athletes: relevance to pre-participation screening.J Am Coll Cardiol. 2008 Mar 11;51(10):1033-9. doi: 10.1016/j.jacc.2007.10.055. J Am Coll Cardiol. 2008. PMID: 18325444
-
Screening for hypertrophic cardiomyopathy in young athletes.N Engl J Med. 1998 Aug 6;339(6):364-9. doi: 10.1056/NEJM199808063390602. N Engl J Med. 1998. PMID: 9691102
-
Syncope, other risk factors, and the implantable defibrillator for sudden death prevention in hypertrophic cardiomyopathy.Anadolu Kardiyol Derg. 2006 Dec;6 Suppl 2:55-60. Anadolu Kardiyol Derg. 2006. PMID: 17162272 Review.
Cited by
-
The ubiquitin proteasome system in human cardiomyopathies and heart failure.Am J Physiol Heart Circ Physiol. 2013 May 15;304(10):H1283-93. doi: 10.1152/ajpheart.00249.2012. Epub 2013 Mar 11. Am J Physiol Heart Circ Physiol. 2013. PMID: 23479263 Free PMC article. Review.
-
Proteasome biology and therapeutics in cardiac diseases.Transl Res. 2019 Mar;205:64-76. doi: 10.1016/j.trsl.2018.09.003. Epub 2018 Sep 28. Transl Res. 2019. PMID: 30342797 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical